SCHEMBL22601451

SCHEMBL22601451

CC(C)(C)c1cc(N2CCCCC2)ccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 6/20 0.54
CHKA P35790 1/20 0.46
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ELOVL1 Q9BW60 1/20 0.43
TERT O14746 2/20 0.42
LNPEP Q9UIQ6 1/20 0.41
MAP4K4 O95819 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.39
S100B P04271 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22601587 0.98 HRH4 (0.51) HRH4CHKALMNASMN1; SMN2HSD17B10
SCHEMBL20224121 0.85 HRH4 (0.56) HRH4LMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL20224125 0.83 LMNA (0.45) LMNASMN1; SMN2HSD17B10KDM4EMEN1
SCHEMBL20224122 0.83 ADRB2 (0.51) HRH4ALDH1A1HTT
SCHEMBL24008771 0.83 HRH4 (0.50) HRH4CHKALMNASMN1; SMN2HSD17B10
SCHEMBL22601438 0.81 KDM4E (0.45) HRH4LMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL22601526 0.81 CHRNA7 (0.47) HRH4LMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL22601446 0.80 MEN1 (0.43) HRH4LMNASMN1; SMN2HSD17B10MEN1
SCHEMBL22601437 0.79 LMNA (0.49) LMNASMN1; SMN2HSD17B10TSHRMEN1
SCHEMBL22601449 0.79 HSD17B10 (0.55) LMNASMN1; SMN2HSD17B10TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200339530-A1 UREA DERIVATIVES AS INHIBITORS OF ASK1 HEPAGENE THERAPEUTICS, INC. (VG) 2020-10-29 US disclosed
US-20160303110-A1 METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY AUSPEX PHARMACEUTICALS, INC. (US) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160303110-A1 METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY PYGM, TNNC1, MUSK HRH4 3715/4885CHKA 927/4885LMNA 645/4885
US-20200339530-A1 UREA DERIVATIVES AS INHIBITORS OF ASK1 ATF1, ERN1, MAP3K1 HRH4 4032/4885CHKA 899/4885LMNA 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.